Currently, five biologics are approved for treatment of GC: Herceptin (trastuzumab) and Enhertu (trastuzumab deruxtecan) which target human epidermal growth factor receptor 2 (HER2), Keytruda (pembrolizumab) and Opdivo (nivolumab) which target programmed death 1 (PD‐1), and Cyramza (ramucirumab) which targets vascular endothelial growth factor receptor (VEGFR). This evidence concerns the gene ERBB2 and gastric cancer.